Journal of Gastric Cancer

  • 제17권4호
  • /
  • Pages.363-373
  • /
  • 2017
  • /
  • 2093-582X(pISSN)
  • /
  • 2093-5641(eISSN)
대한위암학회 (The Korean Gastric Cancer Association)
권호 표지
DOI QR코드

DOI QR Code

Clinicopathological Significance of Large Tumor Suppressor (LATS) Expression in Gastric Cancer

  • Son, Myoung Won (Department of Surgery, Soonchunhyang University Cheonan Hospita) ;
  • Song, Geum Jong (Department of Surgery, Soonchunhyang University Cheonan Hospita) ;
  • Jang, Si-Hyong (Department of Pathology, Soonchunhyang University Cheonan Hospital) ;
  • Hong, Soon Auck (Department of Pathology, Soonchunhyang University Cheonan Hospital) ;
  • Oh, Mee-Hye (Department of Pathology, Soonchunhyang University Cheonan Hospital) ;
  • Lee, Ji-Hye (Department of Pathology, Soonchunhyang University Cheonan Hospital) ;
  • Baek, Moo Jun (Department of Surgery, Soonchunhyang University Cheonan Hospita) ;
  • Lee, Moon Soo (Department of Surgery, Soonchunhyang University Cheonan Hospita)
  • 투고 : 2017.08.01
  • 심사 : 2017.12.15
  • 발행 : 2017.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: The aims of this study were to evaluate the expression of the large tumor suppressor (LATS) genes LATS1 and LATS2 by immunohistochemical staining of gastric cancer, and to evaluate the clinicopathological significance of LATS expression and its correlation with overall survival (OS). Materials and Methods: LATS1 and LATS2 expression in a tissue microarray was detected by immunohistochemistry, using 264 gastric cancer specimens surgically resected between July 2006 and December 2009. Results: Low expression of LATS1 was significantly associated with more advanced American Joint Committee on Cancer (AJCC) stage (P=0.001) and T stage (P=0.032), lymph node (LN) metastasis (P=0.040), perineural invasion (P=0.042), poor histologic grade (P=0.007), and diffuse-type histology by the Lauren classification (P=0.033). Low expression of LATS2 was significantly correlated with older age (${\geq}65$, P=0.027), more advanced AJCC stage (P=0.001) and T stage (P=0.001), LN metastasis (P=0.004), perineural invasion (P=0.004), poor histologic grade (P<0.001), and diffuse-type histology by the Lauren classification (P<0.001). Kaplan-Meier survival analysis revealed significantly poor OS rates in the groups with low LATS1 (P=0.037) and LATS2 (P=0.037) expression. Conclusions: Expression of LATS1 or LATS2 is a significant marker for a good prognosis in patients with gastric cancer.

키워드

참고문헌

  1. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer 2009;125:666-673. https://doi.org/10.1002/ijc.24290
  2. Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, et al. Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann Oncol 2013;24:2657-2671. https://doi.org/10.1093/annonc/mdt301
  3. Oh CM, Won YJ, Jung KW, Kong HJ, Cho H, Lee JK, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat 2016;48:436-450. https://doi.org/10.4143/crt.2016.089
  4. Justice RW, Zilian O, Woods DF, Noll M, Bryant PJ. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev 1995;9:534-546. https://doi.org/10.1101/gad.9.5.534
  5. Xu T, Wang W, Zhang S, Stewart RA, Yu W. Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development 1995;121:1053-1063.
  6. Visser S, Yang X. LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle 2010;9:3892-3903. https://doi.org/10.4161/cc.9.19.13386
  7. Oh HJ, Lee KK, Song SJ, Jin MS, Song MS, Lee JH, et al. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res 2006;66:2562-2569. https://doi.org/10.1158/0008-5472.CAN-05-2951
  8. Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 2010;24:862-874. https://doi.org/10.1101/gad.1909210
  9. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007;21:2747-2761. https://doi.org/10.1101/gad.1602907
  10. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009;16:425-438. https://doi.org/10.1016/j.ccr.2009.09.026
  11. Xia H, Qi H, Li Y, Pei J, Barton J, Blackstad M, et al. LATS1 tumor suppressor regulates G2/M transition and apoptosis. Oncogene 2002;21:1233-1241. https://doi.org/10.1038/sj.onc.1205174
  12. Zeng Q, Hong W. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell 2008;13:188-192. https://doi.org/10.1016/j.ccr.2008.02.011
  13. Zhou Y, Tao F, Cheng Y, Xu F, Yao F, Feng D, et al. Up-regulation of ITCH is associated with down-regulation of LATS1 during tumorigenesis and progression of cervical squamous cell carcinoma. Clin Invest Med 2014;37:E384-E394. https://doi.org/10.25011/cim.v37i6.22243
  14. Morinaga N, Shitara Y, Yanagita Y, Koida T, Kimura M, Asao T, et al. Molecular analysis of the h-warts/LATS1 gene in human breast cancer. Int J Oncol 2000;17:1125-1129.
  15. Li H, Wolfe A, Septer S, Edwards G, Zhong X, Abdulkarim AB, et al. Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int 2012;32:38-47. https://doi.org/10.1111/j.1478-3231.2011.02646.x
  16. Xu ZP, Zhu JS, Zhang Q, Wang XY. A breakdown of the Hippo pathway in gastric cancer. Hepatogastroenterology 2011;58:1611-1617.
  17. Kim KJ, Jung HY, Oh MH, Cho H, Lee JH, Lee HJ, et al. Loss of ARID1A expression in gastric cancer: correlation with mismatch repair deficiency and clinicopathologic features. J Gastric Cancer 2015;15:201-208. https://doi.org/10.5230/jgc.2015.15.3.201
  18. Tao W, Zhang S, Turenchalk GS, Stewart RA, St John MA, Chen W, et al. Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nat Genet 1999;21:177-181. https://doi.org/10.1038/5960
  19. Yabuta N, Fujii T, Copeland NG, Gilbert DJ, Jenkins NA, Nishiguchi H, et al. Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the Drosophila tumor suppressor gene lats/warts. Genomics 2000;63:263-270. https://doi.org/10.1006/geno.1999.6065
  20. Furth N, Ben-Moshe NB, Pozniak Y, Porat Z, Geiger T, Domany E, et al. Down-regulation of LATS kinases alters p53 to promote cell migration. Genes Dev 2015;29:2325-2330. https://doi.org/10.1101/gad.268185.115
  21. Powzaniuk M, McElwee-Witmer S, Vogel RL, Hayami T, Rutledge SJ, Chen F, et al. The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor. Mol Endocrinol 2004;18:2011-2023. https://doi.org/10.1210/me.2004-0065
  22. Yu T, Bachman J, Lai ZC. Evidence for a tumor suppressor role for the large tumor suppressor genes LATS1 and LATS2 in human cancer. Genetics 2013;195:1193-1196. https://doi.org/10.1534/genetics.113.156372
  23. Lin XY, Zhang XP, Wu JH, Qiu XS, Wang EH. Expression of LATS1 contributes to good prognosis and can negatively regulate YAP oncoprotein in non-small-cell lung cancer. Tumour Biol 2014;35:6435-6443. https://doi.org/10.1007/s13277-014-1826-z

피인용 문헌

  1. High Yes-associated protein 1 with concomitant negative LATS1/2 expression is associated with poor prognosis of advanced gastric cancer vol.51, pp.3, 2017, https://doi.org/10.1016/j.pathol.2019.01.001
  2. Outcome in serous ovarian cancer is not associated with LATS expression vol.145, pp.11, 2017, https://doi.org/10.1007/s00432-019-03037-4
  3. Role of LATS1/2 in Prognosis of Advanced Gastric Cancer and Its Relationship With the Tumor Immune Microenvironment vol.10, pp.None, 2020, https://doi.org/10.3389/fonc.2020.01406
  4. The novel long non-coding RNA LATS2-AS1-001 inhibits gastric cancer progression by regulating the LATS2/YAP1 signaling pathway via binding to EZH2 vol.20, pp.None, 2017, https://doi.org/10.1186/s12935-020-01285-w
  5. Pathological significance and prognostic role of LATS2 in prostate cancer vol.81, pp.15, 2021, https://doi.org/10.1002/pros.24226
  6. Reciprocal Regulation of Hippo and WBP2 Signalling-Implications in Cancer Therapy vol.10, pp.11, 2021, https://doi.org/10.3390/cells10113130